Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | KIF11 | P52732 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11511029 | 0.90 | TSHR (0.60) | MEN1KMT2ATSHRESR1ESR2 | |
| SCHEMBL249404 | 0.87 | KMT2A (0.55) | MEN1KMT2ATSHRESR1ESR2 | |
| SCHEMBL11336793 | 0.86 | MEN1 (0.46) | MEN1KMT2ATSHRESR1ESR2 | |
| Ammonia Solution, Strong SCHEMBL11855911 | 0.85 | KMT2A (0.52) | MEN1KMT2ATSHRESR1ESR2 | |
| SCHEMBL24129902 | 0.83 | TSHR (0.75) | MEN1KMT2ATSHRALDH1A1KIF11 | |
| SCHEMBL11475050 | 0.83 | CYP19A1 (0.57) | MEN1KMT2ATSHRALDH1A1KIF11 | |
| SCHEMBL2862802 | 0.83 | MEN1 (0.50) | MEN1KMT2ATSHRESR1ESR2 | |
| SCHEMBL813126 | 0.83 | CYP19A1 (0.57) | MEN1KMT2ATSHRALDH1A1KIF11 | |
| SCHEMBL7768882 | 0.83 | MEN1 (0.50) | MEN1KMT2ATSHRESR1ESR2 | |
| SCHEMBL19130466 | 0.82 | KMT2A (0.41) | MEN1KMT2ATSHRESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889719-B2 | Fluorescent dye, preparation method therefor and use thereof | SHENZHEN UNIVERSITY (CN) | 2021-01-12 | — | — | US | disclosed |
| US-9996007-B2 | Polymer for preparing resist underlayer film, resist underlayer film composition containing the polymer and method for manufacturing semiconductor device using the composition | SK INNOVATION CO., LTD. (KR) | 2018-06-12 | — | — | US | disclosed |
| US-9989849-B2 | Chemically amplified resist material and resist pattern-forming method | JSR CORPORATION (JP) | 2018-06-05 | — | — | US | disclosed |
| US-9939729-B2 | Resist pattern-forming method | JSR CORPORATION (JP) | 2018-04-10 | — | — | US | disclosed |
| EP-2220083-B1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20170131634-A1 | CHEMICALLY AMPLIFIED RESIST MATERIAL AND RESIST PATTERN-FORMING METHOD | JSR CORPORATION (JP) | 2017-05-11 | — | — | US | disclosed |
| US-20170075221-A1 | CHEMICALLY AMPLIFIED RESIST MATERIAL AND RESIST PATTERN-FORMING METHOD | JSR CORPORATION (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170075224-A1 | RESIST PATTERN-FORMING METHOD | JSR CORPORATION (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170015779-A1 | Polymer for Preparing Resist Underlayer Film, Resist Underlayer Film Composition Containing the Polymer and Method for Manufacturing Semiconductor Device Using the Composition | SK GEO CENTRIC CO., LTD. (KR) | 2017-01-19 | — | — | US | disclosed |
| US-8859535-B2 | Hydroxy substituted isoquinolinone derivatives | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | disclosed |
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | WHITEFORD JEFFERY A (US) | 2013-04-04 | — | — | US | disclosed |
| US-20120214988-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | SEKISUI MEDICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| US-8227635-B2 | Apparatus and method for carrying out multiple reactions | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20090299102-A1 | APPARATUS AND METHOD FOR CARRYING OUT MULTIPLE REACTIONS | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009062676-A2 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| CN-1651371-A | Preparation method of 1,1-diaryl-3-propylene halide | UNIV TIANJIN (CN) | 2005-08-10 | — | — | CN | disclosed |
| US-5112851-A | Agricultural Fungicides | SANDOZ LTD. (CH) | 1992-05-12 | — | — | US | disclosed |
| US-4939148-A | Amine derivatives, processes for their production and their use | SANDOZ, LTD. (CH) | 1990-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299102-A1 | APPARATUS AND METHOD FOR CARRYING OUT MULTIPLE REACTIONS | DDO, APEX1, MMAB | MEN1 111/4885KMT2A 922/4885TSHR 2913/4885 |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRIA2 | MEN1 3993/4885KMT2A 719/4885TSHR 320/4885 |
| US-20120214988-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | ADH1C, ADH1A, DERA | MEN1 1119/4885KMT2A 501/4885TSHR 2806/4885 |
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | SBDS, NCL, INTS6 | MEN1 1259/4885KMT2A 3432/4885TSHR 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.